Parameter
| Biomarker | sPD-L1 | Full name | Soluble Programmed Death-Ligand 1 | Molecular Type | protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | assessment of immune status and prognosis | ||
| Disease | Multiple Myeloma (MM) | Disease Subtypes | / | ||
| Organ | Bone marrow, Serum | Test Sample / Technology Platform | serum、marrow | ||
| Pathobiological Mechanisms | sPD-L1 inhibits T cell activity; | ||||
| Clinical Availability Status | research verification | ||||
| Notes and Dynamics | sPD-L1 levels are associated with MRD positivity and predict the efficacy of pembrolizumab; a decrease in sPD-L1 after ASCT indicates immune recovery and prolongs PFS. | ||||